

Defendants.

## ORDER

On November 1, 2023, Eli Sporn, Individually and on behalf of all others similarly situated, filed a complaint in 23-CV-9630. On February 14, 2024, Mhairi Porteous, derivatively on behalf of Brainstorm Cell Therapeutics Inc. filed a complaint in 24-CV-1095. On February 15, 2024, Plaintiff Serge Andrev, derivatively on behalf of Brainstorm Cell Therapeutics, Inc. filed a complaint in 24-CV-01101.

On February 28, 2024, Plaintiff and Defendants in *Sporn v. Brainstorm Cell Therapeutics Inc. et al.*, 23-CV-9630, filed timely oppositions to consolidating the above-captioned cases. *See* ECF Nos. 24-25. At this time, the three above-captioned cases will not be consolidated.


Defendants in *Sporn v. Brainstorm Cell Therapeutics Inc. et al.*, intend to file a Motion to Dismiss by May 31, 2024, *See* ECF No. 21, which would stay discovery under the Private Securities Litigation Reform Act (“PSLRA”). 15 U.S.C. § 78u-4(b)(3)(B). The Court is inclined to stay proceedings in 24-CV-1095 and 24-CV-1101. All parties in 24-CV-1095 and 24-CV-1101 shall meet and confer and file a status letter on ECF by **March 29, 2024**. Such a letter shall describe whether parties agree to stay proceedings or propose next steps.

It is further ORDERED that the named plaintiffs shall promptly serve a copy of this Order on each of the non-appearing defendants and file proof of service on the docket by **March 8, 2024**.

The Clerk of Court is respectfully requested close ECF No. 24 and to docket this order in all the above-captioned cases.

SO ORDERED.

Dated: March 4, 2024  
New York, New York

  
\_\_\_\_\_  
DALE E. HO  
United States District Judge